Report Scope
- Countries: United States, Canada
- Modalities: CT, MRI, X ray/DR, Ultrasound, PET/Nuclear
- Clinical Areas: Oncology, Neurology/Stroke, Cardiology, Respiratory/Lung, MSK/Ortho, General
- Applications: Triage -> detection -> reconstruction -> integration
- Revenue Streams: Hardware, Software, Services, Cloud/Pay per Use
- End use: Hospitals/IDNs, Imaging Centers, Clinics, Teleradiology, Other. (Section 2, Objective & Scope.)
Methodology
Dual lens approach: top down reconciliation to NA totals and country splits; bottom up attach rate engine by modality with factory vs retrofit mixes, ASP bands, and NA specific evidence weights (FDA/Health Canada cadence, reimbursement signals, enterprise buying, and RWE).
Report Snapshot
- Trajectory: North America expands to ~US$13.2B by 2032 (~30% CAGR) . (Executive Summary, p.10; Table 1, p.14.)
- Attach rate headroom: OEM AI ships on ~20% of new CT and ~15% of new MR-ample runway across ultrasound and PET. (Attach rate discussion & Figure 3, pp.18-19.)
What's Driving the Numbers
- Reimbursement pull: The U.S. continues to dominate-about 9-to-1 versus Canada-thanks to CMS NTAP renewals (stroke AI) and the emerging CPT stack for CT-FFR, echo strain and breast-AI.
- Enterprise buying power: Large U.S. IDNs lock multi-year "AI-store" licenses, scaling spend faster than underlying scan growth.
- Regulatory clarity: FDA's Predetermined Change-Control Plan draft allows algorithm upgrades without re-filing, shortening refresh cycles and feeding ARR.
- Canada's catch-up: Single-payer provinces move more cautiously, but national lung-cancer screening pilots and CADTH's positive HTA for TB AI push adoption. The lower 29 % CAGR still doubles market size every three years.
- Cross-border vendors: U.S. cloud-AI providers increasingly win Canadian tenders once privacy compliance (PIPEDA/HIPAA) is proven, further narrowing the gap.
Report Benefits
- Where to play / how to win: NA GTM Growth & Maturity Matrix, competitive dataset, regulatory velocity, and M&A watchlist. (Figures & tables, pp.15-18.)
- Country playbooks: U.S. & Canada GTM radars, channel/pricing matrices, customer tier potential, and timelines with 12 month action cues. (U.S. pp.31-38; Canada pp.52-54.)
- Forecast depth: Breakouts by country, modality, clinical area, application, revenue stream, and end use through 2032. (Tables across pp.24-30, 43-51.)